Gastrointestinal Cancer

James L. Abbruzzese, MD, discusses the underlying disparity between high-volume centers and community medical centers affecting patients with pancreatic cancer.

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses the benefits patients receive with regorafenib for the treatment of colorectal cancer.

The FDA has approved everolimus for the treatment of adult patients with progressive, well-differentiated non-functional, locally advanced or metastatic gastrointestinal or lung neuroendocrine tumors.

Jennifer Wu, MD, reviews recently approved agents in refractory colorectal cancer, as well as biomarker-directed emerging therapies in the setting.

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, explains the benefits of genetic testing for colorectal cancer (CRC) and how oncologists can discuss it with their patients.

Experts in the field assert that the path forward requires a paradigm shift toward integrative analyses that encompass multiple classes of genomic aberrations and consensus classification of CRC based on genomic data to facilitate more effective management of this disease.